Steven Scala's questions to Bristol-Myers Squibb Co (BMY) leadership • Q2 2025
Question
Steven Scala from TD Cowen asked for an update on the path forward for the COBENFI ARISE data and for clarification on the filing status of SOTYKTU in psoriatic arthritis and the confidence level in its lupus and Sjogren's programs.
Answer
EVP & Chief Medical Officer Samit Hirawat confirmed that SOTYKTU has been submitted for psoriatic arthritis. Regarding the ARISE data, he stated that analysis is ongoing and no discussions with regulators have occurred yet. He expressed confidence in the lupus and Sjogren's programs, noting they are based on positive Phase 2 data and are enrolling well.